DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
Status:
Unknown status
Trial end date:
2020-07-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate of the clinical efficacy and safety of DLAAG
protocol in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome with
blast excess